Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment

References

• Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474(7351):298–306. doi:10.1038/nature10208
   PubMed Web of Science ®Google Scholar
• Alatab S, Sepanlou SG, Ikuta K. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. doi:10.1016/S2468-1253(19)30333-4
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56–66. doi:10.1038/s41575-020-00360-x
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417–429. doi:10.1056/NEJMra020831
   PubMed Web of Science ®Google Scholar
• Ott C, Schoelmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10(10):585–595. doi:10.1038/nrgastro.2013.117
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Puttini PS, Cassinotti A, et al. Extraintestinal manifestations of inflammatory bowel disease. Digestive Liver Dis. 2008;40:S253–S259. doi:10.1016/S1590-8658(08)60534-4
   Google Scholar
• Ganji-Arjenaki M, Rafieian-Kopaei M, Malekzadeh M. Phytotherapies in inflammatory bowel disease. J Res Med Sci. 2019;24:24. doi:10.4103/jrms.JRMS_363_18
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15(1):39–49. doi:10.1038/nrgastro.2017.136
   PubMed Web of Science ®Google Scholar
• Bruner LP, White AM, Proksell S. Inflammatory bowel disease. Prim Care. 2023;50(3):411–427. doi:10.1016/j.pop.2023.03.009
   PubMed Web of Science ®Google Scholar
• Zhang S, Langer R, Traverso G. Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. Nano Today. 2017;16:82–96. doi:10.1016/j.nantod.2017.08.006
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Lautenschläger C, Schmidt C, Fischer D, et al. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Delivery Rev. 2014;71:58–76. doi:10.1016/j.addr.2013.10.001
   PubMed Web of Science ®Google Scholar
• Coco R, Plapied L, Pourcelle V, et al. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm. 2013;440(1):3–12. doi:10.1016/j.ijpharm.2012.07.017
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ghosh S, Sil PC. Role of nanostructures in improvising oral medicine. Toxicol Rep. 2019;6:358–368. doi:10.1016/j.toxrep.2019.04.004
   PubMed Web of Science ®Google Scholar
• Kietzmann D, Moulari B, Béduneau A, et al. Colonic delivery of carboxyfluorescein by pH-sensitive microspheres in experimental colitis. Eur J Pharm Biopharm. 2010;76(2):290–295. doi:10.1016/j.ejpb.2010.06.013
   PubMed Web of Science ®Google Scholar
• Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009;58(2):233–240. doi:10.1136/gut.2008.154302
   PubMed Web of Science ®Google Scholar
• Date AA, Halpert G, Babu T, et al. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials. 2018;185:97–105. doi:10.1016/j.biomaterials.2018.09.005
   PubMed Web of Science ®Google Scholar
• Jeevanandam J, Barhoum A, Chan YS, et al. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. 2018;9:1050–1074. doi:10.3762/bjnano.9.98
   PubMed Web of Science ®Google Scholar
• Brakmane G, Winslet M, Seifalian AM. Systematic review: the applications of nanotechnology in gastroenterology. Aliment. Pharmacol Ther. 2012;36(3):213–221. doi:10.1111/j.1365-2036.2012.05179.x
   PubMed Web of Science ®Google Scholar
• Pontes AP, Welting TJM, Rip J, et al. Polymeric nanoparticles for drug delivery in osteoarthritis. Pharmaceutics. 2022;14(12):2639. doi:10.3390/pharmaceutics14122639
   PubMed Web of Science ®Google Scholar
• Marasini N, Er G, Fu C, et al. Development of a hyperbranched polymer-based methotrexate nanomedicine for rheumatoid arthritis. Acta Biomater. 2022;142:298–307. doi:10.1016/j.actbio.2022.01.054
   PubMed Web of Science ®Google Scholar
• Mai Y, Ouyang Y, Yu M, et al. Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. J Control Release. 2022;349:354–366. doi:10.1016/j.jconrel.2022.07.006
   PubMed Web of Science ®Google Scholar
• Brusini R, Varna M, Couvreur P. Advanced nanomedicines for the treatment of inflammatory diseases. Adv Drug Delivery Rev. 2020;157:161–178. doi:10.1016/j.addr.2020.07.010
   PubMed Web of Science ®Google Scholar
• Gazzaniga A, Maroni A, Sangalli ME, et al. Time-controlled oral delivery systems for colon targeting. Expert Opin Drug Delivery. 2006;3(5):583–597. doi:10.1517/17425247.3.5.583
   PubMedGoogle Scholar
• Beloqui A, Coco R, Alhouayek M, et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int J Pharm. 2013;454(2):775–783. doi:10.1016/j.ijpharm.2013.05.017
   PubMedGoogle Scholar
• Jakubiak P, Thwala LN, Cadete A, et al. Solvent-free protamine nanocapsules as carriers for mucosal delivery of therapeutics. Eur Polym J. 2017;93:695–705. doi:10.1016/j.eurpolymj.2017.03.049
   Web of Science ®Google Scholar
• El-Hady SM, AbouGhaly MH, El-Ashmoony MM, et al. Colon targeting of celecoxib nanomixed micelles using pulsatile drug delivery systems for the prevention of inflammatory bowel disease. Int J Pharm. 2020;576:118982.
   PubMedGoogle Scholar
• Ali H, Weigmann B, Collnot E-M, et al. Budesonide loaded PLGA nanoparticles for targeting the inflamed intestinal mucosa-pharmaceutical characterization and fluorescence imaging. Pharm Res. 2016;33(5):1085–1092. doi:10.1007/s11095-015-1852-6
   PubMed Web of Science ®Google Scholar
• Vaezi Z, Aghdaei HA, Sedghi M, et al. Hemoglobin bio-adhesive nanoparticles as a colon-specific delivery system for sustained release of 5-aminosalicylic acid in the effective treatment of inflammatory bowel disease. Int J Pharm. 2022;616:121531.
   PubMedGoogle Scholar
• Amaldoss MJN, Ahmed I, Kumar J, et al. Therapeutic efficacy of rifaximin loaded tamarind gum polysaccharide nanoparticles in TNBS induced IBD model Wistar rats. Rep Pract Oncol Radiother. 2021;26(5):712–729. doi:10.5603/RPOR.a2021.0100
   PubMedGoogle Scholar
• Oh C, Lee W, Park J, et al. Development of spleen targeting H 2 s donor loaded liposome for the effective systemic immunomodulation and treatment of inflammatory bowel disease. ACS nano. 2023;17:4327–4345. doi:10.1021/acsnano.2c08898
   PubMed Web of Science ®Google Scholar
• Huguet-Casquero A, Xu Y, Gainza E, et al. Oral delivery of oleuropein-loaded lipid nanocarriers alleviates inflammation and oxidative stress in acute colitis. Int J Pharm. 2020;586:119515.
   PubMedGoogle Scholar
• Kim JM, Kim DH, Park HJ, et al. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. J Nanobiotechnol. 2020;18(1). doi:10.1186/s12951-020-00693-4
   Web of Science ®Google Scholar
• Li X, Hetjens L, Wolter N, et al. Charge-reversible and biodegradable chitosan-based microgels for lysozyme-triggered release of vancomycin. J Adv Res. 2023;43:87–96. doi:10.1016/j.jare.2022.02.014
   PubMed Web of Science ®Google Scholar
• Cheng S, Shen H, Zhao S, et al. Orally administered mesoporous silica capped with the cucurbit 8 uril complex to combat colitis and improve intestinal homeostasis by targeting the gut microbiota. Nanoscale. 2020;12(28):15348–15363. doi:10.1039/D0NR03037F
   PubMed Web of Science ®Google Scholar
• Moulari B, Pertuit D, Pellequer Y, et al. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials. 2008;29(34):4554–4560. doi:10.1016/j.biomaterials.2008.08.009
   PubMed Web of Science ®Google Scholar
• Wang X, Yan -J-J, Wang L, et al. Rational design of polyphenol-poloxamer nanovesicles for targeting inflammatory bowel disease therapy. Chem Mater. 2018;30(12):4073–4080. doi:10.1021/acs.chemmater.8b01173
   Web of Science ®Google Scholar
• Penate Medina T, Pan J, Damoah C, et al. Utilizing sphingomyelinase sensitizing liposomes in imaging intestinal inflammation in dextran sulfate sodium-induced murine colitis. Biomedicines. 2022;10(2):413. doi:10.3390/biomedicines10020413
   PubMed Web of Science ®Google Scholar
• Priyam A, Shivhare K, Yadav S, et al. Enhanced solubility and self-assembly of amphiphilic sulfasalazine-PEG-OMe (S-PEG) conjugate into core-shell nanostructures useful for colonic drug delivery. Colloids Surfaces, A. 2018;547:157–167.
   Google Scholar
• Ferri D, Gaviña P, Parra M, et al. Mesoporous silica microparticles gated with a bulky azo derivative for the controlled release of dyes/drugs in colon. Royal Soc Open Sci. 2018;5(8):180873. doi:10.1098/rsos.180873
   PubMed Web of Science ®Google Scholar
• Xu C, Chen S, Chen C, et al. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy. Int J Pharm. 2022;623:121884.
   PubMedGoogle Scholar
• Li S, Xie A, Li H, et al. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease. J Control Release. 2019;316:66–78. doi:10.1016/j.jconrel.2019.10.054
   PubMed Web of Science ®Google Scholar
• Zhang Q, Tao H, Lin Y, et al. A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease. Biomaterials. 2016;105:206–221. doi:10.1016/j.biomaterials.2016.08.010
   PubMed Web of Science ®Google Scholar
• Thu-Ha Thi N, Trinh N-T, Tran HN, et al. Improving silymarin oral bioavailability using silica-installed redox nanoparticle to suppress inflammatory bowel disease. J Control Release. 2021;331:515–524. doi:10.1016/j.jconrel.2020.10.042
   PubMed Web of Science ®Google Scholar
• Xu J, Shi T, Zhang Y, et al. Probiotic-inspired nanomedicine restores intestinal homeostasis in colitis by regulating redox balance, immune responses, and the gut microbiome. Adv Mater. 2022;35(3):2207890.
   Web of Science ®Google Scholar
• Zhang D, Wei Y, Chen K, et al. Biocompatible Reactive Oxygen Species (ROS)-responsive nanoparticles as superior drug delivery vehicles. Adv Healthcare Mater. 2015;4(1):69–76. doi:10.1002/adhm.201400299
   Web of Science ®Google Scholar
• Qelliny MR, Aly UF, Elgarhy OH, et al. Budesonide-loaded eudragit s 100 nanocapsules for the treatment of acetic acid-induced colitis in animal model. AAPS Pharm Sci Tech. 2019;20(6). doi:10.1208/s12249-019-1453-5
   PubMed Web of Science ®Google Scholar
• Zhang L, Li M, Zhang G, et al. Micro- and nanoencapsulated hybrid delivery system (MNEHDS): a novel approach for colon-targeted oral delivery of berberine. Mol Pharmaceut. 2021;18(4):1573–1581. doi:10.1021/acs.molpharmaceut.0c00970
   PubMed Web of Science ®Google Scholar
• Mutalik S, Suthar NA, Managuli RS, et al. Development and performance evaluation of novel nanoparticles of a grafted copolymer loaded with curcumin. Int J Biol Macromol. 2016;86:709–720. doi:10.1016/j.ijbiomac.2015.11.092
   PubMed Web of Science ®Google Scholar
• Cao J, Cheng J, Xi S, et al. Alginate/chitosan microcapsules for in-situ delivery of the protein, interleukin-1 receptor antagonist (IL-1Ra), for the treatment of dextran sulfate sodium (DSS)-induced colitis in a mouse model. Eur J Pharm Biopharm. 2019;137:112–121. doi:10.1016/j.ejpb.2019.02.011
   PubMed Web of Science ®Google Scholar
• Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int J Pharm. 2006;316(1–2):138–143. doi:10.1016/j.ijpharm.2006.01.032
   PubMed Web of Science ®Google Scholar
• Jiang J, Xiao J, Zhao Z, et al. One-step prepared nano-in-micro microcapsule delivery vehicle with sequential burst-sustained drug release for the targeted treatment of inflammatory bowel disease. Mater Chem Front. 2021;5(16):6027–6040. doi:10.1039/D1QM00589H
   Web of Science ®Google Scholar
• Ali H, Weigmann B, Neurath MF, et al. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Control Release. 2014;183:167–177. doi:10.1016/j.jconrel.2014.03.039
   PubMed Web of Science ®Google Scholar
• Markam R, Bajpai J, Bajpai AK. Synthesis of ginger derived nanocarriers (GDNC) and study of in vitro release of 5-amino salicylic acid (5-ASA) as an anti inflammatory drug. J Drug Delivery Sci Technol. 2019;50:355–364. doi:10.1016/j.jddst.2019.01.039
   Web of Science ®Google Scholar
• Dong Y, Zhou Z, Ding H, et al. Preparation and properties of a pH sensitive carrier based on three kinds of polymer blend to control the release of 5-amino salicylic acid. Pharmaceut Develop Technol. 2014;19(8):960–967. doi:10.3109/10837450.2013.846372
   PubMed Web of Science ®Google Scholar
• Jacob EM, Borah A, Pillai SC, et al. Garcinol encapsulated ph-sensitive biodegradable nanoparticles: a novel therapeutic strategy for the treatment of inflammatory bowel disease. Polymers. 2021;13(6):862. doi:10.3390/polym13060862
   PubMed Web of Science ®Google Scholar
• Duan H, Lü S, Gao C, et al. Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon. Colloids Surf B Biointerfaces. 2016;145:510–519. doi:10.1016/j.colsurfb.2016.05.038
   PubMed Web of Science ®Google Scholar
• Qu Z, Wong KY, Moniruzzaman M, et al. One-pot synthesis of pH-responsive eudragit-mesoporous silica nanocomposites enable colonic delivery of glucocorticoids for the treatment of inflammatory bowel disease. Adv Ther. 2021;4(2). doi:10.1002/adtp.202000165
   Google Scholar
• Kesharwani SS, Ahmad R, Bakkari MA, et al. Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): formulation development, characterization and pharmacological evaluation. J Control Release. 2018;290:165–179.
   PubMed Web of Science ®Google Scholar
• Kshirsagar SJ, Bhalekar MR, Patel JN, et al. Preparation and characterization of nanocapsules for colon-targeted drug delivery system. Pharmaceut Develop Technol. 2012;17(5):607–613. doi:10.3109/10837450.2011.557732
   PubMed Web of Science ®Google Scholar
• Nguyen CTH, Webb RI, Lambert LK, et al. Bifunctional succinylated epsilon-polylysine-coated mesoporous silica nanoparticles for pH-responsive and intracellular drug delivery targeting the colon. ACS Appl Mater Interfaces. 2017;9(11):9470–9483. doi:10.1021/acsami.7b00411
   PubMed Web of Science ®Google Scholar
• Naeem M, Kim W, Cao J, et al. Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon. Colloids Surf B Biointerfaces. 2014;123:271–278. doi:10.1016/j.colsurfb.2014.09.026
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alvarez M, Coll C, Gonzalez-Alvarez I, et al. Gated mesoporous silica nanocarriers for a “two-step” targeted system to colonic tissue. Mol Pharmaceut. 2017;14(12):4442–4453. doi:10.1021/acs.molpharmaceut.7b00565
   PubMed Web of Science ®Google Scholar
• Bertoni S, Liu Z, Correia A, et al. pH and reactive oxygen species-sequential responsive nano-in-micro composite for targeted therapy of inflammatory bowel disease. Adv Funct Mater. 2018;28(50):1806175.
   Web of Science ®Google Scholar
• Wang X, Yan J, Wang L, et al. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Theranostics. 2020;10(23):10808–10822. doi:10.7150/thno.47601
   PubMed Web of Science ®Google Scholar
• Teruel AH, Pérez-Esteve É, González-álvarez I, et al. Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: new approaches for inflammatory bowel diseases treatment. J Control Release. 2018;281:58–69. doi:10.1016/j.jconrel.2018.05.007
   PubMed Web of Science ®Google Scholar
• Wachsmann P, Moulari B, Béduneau A, et al. Surfactant-dependence of nanoparticle treatment in murine experimental colitis. J Control Release. 2013;172(1):62–68. doi:10.1016/j.jconrel.2013.07.031
   PubMed Web of Science ®Google Scholar
• Zhang S, Cho WJ, Jin AT, et al. Heparin-coated albumin nanoparticles for drug combination in targeting inflamed intestine. Adv Healthcare Mater. 2020;9(16):2000536.
   Web of Science ®Google Scholar
• Zhao S, Li Y, Liu Q, et al. An Orally Administered CeO 2 @montmorillonite nanozyme targets inflammation for inflammatory bowel disease therapy. Adv Funct Mater. 2020;30(45). doi:10.1002/adfm.202004692
   Web of Science ®Google Scholar
• Shrestha N, Xu Y, Prévost JRC, et al. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. Acta Biomater. 2022;140:561–572. doi:10.1016/j.actbio.2021.12.015
   PubMed Web of Science ®Google Scholar
• Li X, Yu M, Zhu Z, et al. Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease. Carbohydr Polym. 2021;273:118556. doi:10.1016/j.carbpol.2021.118556
   PubMed Web of Science ®Google Scholar
• Sunnap O, Subramanian S, Vemula PK, et al. Zingerone-encapsulated solid lipid nanoparticles as oral drug-delivery systems to potentially target inflammatory diseases. Chemnanomat. 2022;8(12). doi:10.1002/cnma.202200388
   Web of Science ®Google Scholar
• Zhang S, Ermann J, Succi MD, et al. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Sci, trans med. 2015;7(300). doi:10.1126/scitranslmed.aaa5657
   Web of Science ®Google Scholar
• Wang C, Guo Z, Liang J, et al. An oral delivery vehicle based on konjac glucomannan acetate targeting the colon for inflammatory bowel disease therapy. Front Bioeng Biotechnol. 2022;10:1025155.
   PubMed Web of Science ®Google Scholar
• Schilrreff P, Simioni YR, Jerez HE, et al. Superoxide dismutase in nanoarchaeosomes for targeted delivery to inflammatory macrophages. Colloids Surf B Biointerfaces. 2019;179:479–487. doi:10.1016/j.colsurfb.2019.03.061
   PubMed Web of Science ®Google Scholar
• Le Z, He Z, Liu H, et al. Antioxidant enzymes sequestered within lipid-polymer hybrid nanoparticles for the local treatment of inflammatory bowel disease. ACS Appl Mater Interfaces. 2021;13(47):55966–55977. doi:10.1021/acsami.1c19457
   PubMed Web of Science ®Google Scholar
• Vafaei SY, Esmaeili M, Amini M, et al. Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa. Carbohydr Polym. 2016;144:371–381. doi:10.1016/j.carbpol.2016.01.026
   PubMed Web of Science ®Google Scholar
• Gong W, Yu J, Zheng T, et al. CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease. Clin Translat Med. 2021;11(2). doi:10.1002/ctm2.339
   Web of Science ®Google Scholar
• Zhang M, Viennois E, Prasad M, et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016;101:321–340. doi:10.1016/j.biomaterials.2016.06.018
   PubMed Web of Science ®Google Scholar
• Shabana S, Hamouda HI, Abdalla M, et al. Multifunctional nanoparticles based on marine polysaccharides for apremilast delivery to inflammatory macrophages: preparation, targeting ability, and uptake mechanism*. Int J Biol Macromol. 2022;222:1709–1722. doi:10.1016/j.ijbiomac.2022.09.225
   PubMed Web of Science ®Google Scholar
• Huang Z, Gan J, Jia L, et al. An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Biomaterials. 2015;48:26–36. doi:10.1016/j.biomaterials.2015.01.013
   PubMed Web of Science ®Google Scholar
• Sinhmar GK, Shah NN, Rawal SU, et al. Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease. Artif Cells Nanomed Biotechnol. 2018;46:565–578. doi:10.1080/21691401.2018.1463232
   PubMed Web of Science ®Google Scholar
• Mao Y, Han M, Chen C, et al. A biomimetic nanocomposite made of a ginger-derived exosome and an inorganic framework for high-performance delivery of oral antibodies. Nanoscale. 2021;13(47):20157–20169. doi:10.1039/D1NR06015E
   PubMed Web of Science ®Google Scholar
• Herminia Higa L, Schilrreff P, Briski AM, et al. Bacterioruberin from Haloarchaea plus dexamethasone in ultra-small macrophage-targeted nanoparticles as potential intestinal repairing agent. Colloids Surf B Biointerfaces. 2020;191:110961.
   PubMed Web of Science ®Google Scholar
• Higa LH, Jerez HE, de Farias MA, et al. Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. Nanomedicine. 2017;12(10):1165–1175. doi:10.2217/nnm-2016-0437
   PubMed Web of Science ®Google Scholar
• Qiu H, Gong H, Bao Y, et al. Reactive oxygen species-scavenging hollow MnO 2 nanozymes as carriers to deliver budesonide for synergistic inflammatory bowel disease therapy. Biomater. Sci. 2022;10(2):457–466. doi:10.1039/D1BM01525G
   PubMed Web of Science ®Google Scholar
• Bao M, Wang K, Li J, et al. ROS scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease. Acta Biomater. 2023;161:250–264. doi:10.1016/j.actbio.2023.02.026
   PubMed Web of Science ®Google Scholar
• Naserifar M, Hosseinzadeh H, Abnous K, et al. Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. Life Sci. 2020;262:118555. doi:10.1016/j.lfs.2020.118555
   PubMed Web of Science ®Google Scholar
• Huang Y, Guo J, Gui S. Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-alpha siRNA provide a novel strategy for the experimental treatment of ulcerative colitis. Eur J Pharm Sci. 2018;125:232–243. doi:10.1016/j.ejps.2018.10.009
   PubMed Web of Science ®Google Scholar
• Wei F, Lang Y, Shen Q, et al. Osteopontin-loaded PLGA nanoparticles enhance the intestinal mucosal barrier and alleviate inflammation via the NF-kappa B signaling pathway. Colloids Surf B Biointerfaces. 2020;190:110952.
   PubMed Web of Science ®Google Scholar
• Lee Y, Sugihara K, Gillilland MG, et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nature Mater. 2020;19(1):118. doi:10.1038/s41563-019-0462-9
   PubMed Web of Science ®Google Scholar
• Kotla NG, Burke O, Pandit A, et al. An orally administrated hyaluronan functionalized polymeric hybrid nanoparticle system for colon-specific drug delivery. Nanomaterials. 2019;9(9):1246. doi:10.3390/nano9091246
   Web of Science ®Google Scholar
• Du Y, Liu Y, Sun L, et al. cRGD peptide incorporated with patchouli alcohol loaded silk fibroin nanoparticles for enhanced targeting of inflammatory sites in colitis. Biomat Advan. 2022;140:101231.
   Google Scholar
• Gan J, Liu Y, Sun L, et al. Orally administrated nucleotide-delivery particles from microfluidics for inflammatory bowel disease treatment. Appl Mater Today. 2021;25:101231.
   Web of Science ®Google Scholar
• Chen Y, Feng J, Chen Y, et al. ROS-responsive nano-medicine for navigating autophagy to enhance targeted therapy of inflammatory bowel disease. Int J Pharm. 2024;659:124117. doi:10.1016/j.ijpharm.2024.124117
   PubMedGoogle Scholar
• Li X, Fang S, Yu Y, et al. Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease. Chem Eng J. 2022;445:136438.
   Web of Science ®Google Scholar
• Sun Q, Arif M, Chi Z, et al. Macrophages-targeting mannosylated nanoparticles based on inulin for the treatment of inflammatory bowel disease (IBD). Int J Biol Macromol. 2021;169:206–215. doi:10.1016/j.ijbiomac.2020.12.094
   PubMed Web of Science ®Google Scholar
• Feng J, Wang Y, Lv Y, et al. XA pH-responsive and colitis-targeted nanoparticle loaded with shikonin for the oral treatment of inflammatory bowel disease in mice. Mol Pharmaceut. 2022;19(11):4157–4170. doi:10.1021/acs.molpharmaceut.2c00550
   PubMed Web of Science ®Google Scholar
• Lv Y, Ren M, Yao M, et al. Colon-specific delivery of methotrexate using hyaluronic acid modified pH-responsive nanocarrier for the therapy of colitis in mice. Int J Pharm. 2023;635:122741. doi:10.1016/j.ijpharm.2023.122741
   PubMedGoogle Scholar
• Attia MF, Anton N, Wallyn J, et al. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185–1198. doi:10.1111/jphp.13098
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang -Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Delivery Rev. 2009;61(2):158–171. doi:10.1016/j.addr.2008.11.002
   PubMed Web of Science ®Google Scholar
• Lum H, Malik AB. Mechanisms of increased endothelial permeability. Can J Physiol Pharmacol. 1996;74(7):787–800. doi:10.1139/y96-081
   PubMed Web of Science ®Google Scholar
• Schulzke JD, Ploeger S, Amasheh M, et al. Epithelial tight junctions in intestinal inflammation. Molecu Struct Funct Tight Junct. 2009;1165:294–300.
   Google Scholar
• Lamprecht A, Yamamoto H, Takeuchi H, et al. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther. 2005;315(1):196–202. doi:10.1124/jpet.105.088146
   PubMed Web of Science ®Google Scholar
• Lamprecht A. IBD Selective nanoparticle adhesion can enhance colitis therapy. Nat Rev Gastroenterol Hepatol. 2010;7(6):311–312. doi:10.1038/nrgastro.2010.66
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001;18(6):788–793. doi:10.1023/A:1011032328064
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–358. doi:10.4103/0250-474X.57282
   PubMed Web of Science ®Google Scholar
• Bondì ML, Montana G, Craparo EF, et al. Lipid nanoparticles as delivery vehicles for the Parietaria judaica major allergen Par j 2. Int J Nanomed. 2011;6:2953–2962. doi:10.2147/IJN.S24264
   PubMed Web of Science ®Google Scholar
• Harel-Adar T, Mordechai TB, Amsalem Y, et al. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci U S A. 2011;108(5):1827–1832. doi:10.1073/pnas.1015623108
   PubMed Web of Science ®Google Scholar
• Song W, Shen L, Wang Y, et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun. 2018;9. doi:10.1038/s41467-018-04605-x
   Web of Science ®Google Scholar
• Zwolinska-Wcislo M, Krzysiek-Maczka G, Ptak-Belowska A, et al. antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines. J Physiol Pharmacol. 2011;62(3):357–368.
   PubMed Web of Science ®Google Scholar
• Ribeiro Paiotti AP, Miszputen SJ, Oshima CTF, et al. Effect of COX-2 inhibitor after TNBS-induced colitis in wistar rats. J Molec Histol. 2009;40(4):317–324. doi:10.1007/s10735-009-9243-0
   PubMed Web of Science ®Google Scholar
• Hong S, Choi DW, Kim HN, et al. Protein-based nanoparticles as drug delivery systems. Pharmaceutics. 2020;12(7):604. doi:10.3390/pharmaceutics12070604
   PubMed Web of Science ®Google Scholar
• Saptarshi SR, Duschl A, Lopata AL. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J Nanobiotechnol. 2013;11:11. doi:10.1186/1477-3155-11-11
   PubMed Web of Science ®Google Scholar
• Nayak AK, Pal D. Tamarind seed polysaccharide: an emerging excipient for pharmaceutical use. Indian J Pharm Educ Res. 2017;51(2):S136–S146. doi:10.5530/ijper.51.2s.60
   Web of Science ®Google Scholar
• Nakajima N, Ishihara K, Matsuura Y. Dietary-fiber-degrading enzymes from a human intestinal Clostridium and their application to oligosaccharide production from nonstarchy polysaccharides using immobilized cells. Appl Microbiol Biotechnol. 2002;59(2–3):182–189. doi:10.1007/s00253-002-1015-7
   PubMed Web of Science ®Google Scholar
• Ahn MY, Shin KH, Kim D-H, et al. Characterization of a Bacteroides species from human intestine that degrades glycosaminoglycans. Can J Microbiol. 1998;44(5):423–429. doi:10.1139/w98-027
   PubMed Web of Science ®Google Scholar
• Collins CE, Rampton DS. Review article: platelets in inflammatory bowel disease--pathogenetic role and therapeutic implications. Aliment Pharmacol Ther. 1997;11(2):237–247. doi:10.1046/j.1365-2036.1997.153328000.x
   PubMed Web of Science ®Google Scholar
• Ballongue J, Schumann C, Quignon P. Effects of lactulose and lactitol on colonic microflora and enzymatic activity. Scand J Gastroenterol Suppl. 1997;222:41–44. doi:10.1080/00365521.1997.11720716
   PubMedGoogle Scholar
• Fahlgren A, Hammarström S, Danielsson Å, et al. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin Exp Immunol. 2003;131(1):90–101. doi:10.1046/j.1365-2249.2003.02035.x
   PubMed Web of Science ®Google Scholar
• Rubio CA. The natural antimicrobial enzyme lysozyme is up-regulated in gastrointestinal inflammatory conditions. Pathogens. 2014;3(1):73–92. doi:10.3390/pathogens3010073
   PubMedGoogle Scholar
• Roldo M, Barbu E, Brown JF, et al. Azo compounds in colon-specific drug delivery. Expert Opin Drug Delivery. 2007;4(5):547–560. doi:10.1517/17425247.4.5.547
   PubMed Web of Science ®Google Scholar
• Cao YH, Cao RH, Brakenhielm E. Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem. 2002;13(7):380–390. doi:10.1016/S0955-2863(02)00204-8
   PubMed Web of Science ®Google Scholar
• Ayissi VBO, Ebrahimi A, Schluesenner H. Epigenetic effects of natural polyphenols: a focus on SIRT1-mediated mechanisms. Mol Nutr Food Res. 2014;58(1):22–32. doi:10.1002/mnfr.201300195
   PubMed Web of Science ®Google Scholar
• Ishida T, Wang X, Shimizu T, et al. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349–355. doi:10.1016/j.jconrel.2007.05.015
   PubMed Web of Science ®Google Scholar
• Sakata A, Ochiai T, Shimeno H, et al. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Immunology. 2007;122(1):54–64. doi:10.1111/j.1365-2567.2007.02612.x
   PubMed Web of Science ®Google Scholar
• Campbell EL, Colgan SP. Control and dysregulation of redox signalling in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2019;16(2):106–120. doi:10.1038/s41575-018-0079-5
   PubMed Web of Science ®Google Scholar
• Simmonds NJ, Rampton DS. Inflammatory bowel disease--a radical view. Gut. 1993;34(7):865–868. doi:10.1136/gut.34.7.865
   PubMed Web of Science ®Google Scholar
• Schulze-Osthoff K, Bauer MK, Vogt M, et al. Oxidative stress and signal transduction. Internat J Vitam Nutr Res. 1997;67(5):336–342.
   PubMed Web of Science ®Google Scholar
• Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet. 1994;344(8926):859–861. doi:10.1016/S0140-6736(94)92831-2
   PubMed Web of Science ®Google Scholar
• Pavlick KP, Laroux FS, Fuseler J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med. 2002;33(3):311–322. doi:10.1016/S0891-5849(02)00853-5
   PubMed Web of Science ®Google Scholar
• Chen L, You Q, Hu L, et al. The antioxidant procyanidin reduces reactive oxygen species signaling in macrophages and ameliorates experimental colitis in mice. Front Immunol. 2017;8:1910. doi:10.3389/fimmu.2017.01910
   PubMed Web of Science ®Google Scholar
• Simmonds NJ, Allen RE, Stevens TRJ, et al. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology. 1992;103(1):186–196. doi:10.1016/0016-5085(92)91112-H
   PubMed Web of Science ®Google Scholar
• Sedghi S, Fields JZ, Klamut M, et al. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut. 1993;34(9):1191–1197. doi:10.1136/gut.34.9.1191
   PubMed Web of Science ®Google Scholar
• Nugent SG, Kumar D, Rampton DS, et al. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571–577. doi:10.1136/gut.48.4.571
   PubMed Web of Science ®Google Scholar
• Palugan L, Cerea M, Zema L, et al. Coated pellets for oral colon delivery. J Drug Delivery Sci Technol. 2015;25:1–15. doi:10.1016/j.jddst.2014.12.003
   Web of Science ®Google Scholar
• Naik JB, Waghulde MR. Development of vildagliptin loaded Eudragit microspheres by screening design: in vitro evaluation. J Pharm Invest. 2018;48(6):627–637. doi:10.1007/s40005-017-0355-3
   Google Scholar
• Madhavi M, Madhavi K, Jithan AV. Preparation and in vitro/in vivo characterization of curcumin microspheres intended to treat colon cancer. J Pharm Bioallied Sci. 2012;4(2):164–171. doi:10.4103/0975-7406.94825
   PubMedGoogle Scholar
• Asfour MH, Mohsen AM. Formulation and evaluation of pH-sensitive rutin nanospheres against colon carcinoma using HCT-116 cell line. J Adv Res. 2018;9:17–26. doi:10.1016/j.jare.2017.10.003
   PubMed Web of Science ®Google Scholar
• Kulkarni RV, Sa B. Evaluation of pH-Sensitivity and Drug Release Characteristics of (Polyacrylamide-Grafted-Xanthan)-Carboxymethyl Cellulose-Based pH-Sensitive interpenetrating network hydrogel beads. Drug Dev Ind Pharm. 2008;34(12):1406–1414. doi:10.1080/03639040802130079
   PubMed Web of Science ®Google Scholar
• Das S, Chaudhury A, Ng K-Y. Preparation and evaluation of zinc-pectin-chitosan composite particles for drug delivery to the colon: role of chitosan in modifying in vitro and in vivo drug release. Int J Pharm. 2011;406(1–2):11–20. doi:10.1016/j.ijpharm.2010.12.015
   PubMedGoogle Scholar
• Ways TMM, Lau WM, Khutoryanskiy VV. Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers. 2018;10(3):267. doi:10.3390/polym10030267
   PubMed Web of Science ®Google Scholar
• Maroni A, Moutaharrik S, Zema L, et al. Enteric coatings for colonic drug delivery: state of the art. Expert Opin Drug Delivery. 2017;14(9):1027–1029. doi:10.1080/17425247.2017.1360864
   PubMed Web of Science ®Google Scholar
• Tirosh B, Khatib N, Barenholz Y, et al. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol Pharmaceut. 2009;6(4):1083–1091. doi:10.1021/mp9000926
   PubMed Web of Science ®Google Scholar
• Wileman TE, Lennartz MR, Stahl PD. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. Proc Natl Acad Sci USA. 1986;83(8):2501–2505. doi:10.1073/pnas.83.8.2501
   PubMed Web of Science ®Google Scholar
• Leonel Parra F, Stoll IK, Zwick M, et al. Make It Simple: (SR-A1+TLR7) Macrophage Targeted NANOarchaeosomes. Front Bioeng Biotechnol. 2018;6:6. doi:10.3389/fbioe.2018.00006
   PubMed Web of Science ®Google Scholar
• Tripodo G, Trapani A, Torre ML, et al. Hyaluronic acid and its derivatives in drug delivery and imaging: recent advances and challenges. Eur J Pharm Biopharm. 2015;97:400–416. doi:10.1016/j.ejpb.2015.03.032
   PubMed Web of Science ®Google Scholar
• de la Motte CA, Kessler SP. The role of hyaluronan in innate defense responses of the intestine. Int J Cell Biol. 2015;2015:481301. doi:10.1155/2015/481301
   PubMedGoogle Scholar
• Mukaida N, Sasaki S-I, Baba T. CCL4 Signaling in the Tumor Microenvironment. In: Birbrair A, editor. Tumor Microenvironment: The Role of Chemokines, Pt A. Springer; 2020:23–32.
   Google Scholar
• Schreiber S, Perkins SL, Teitelbaum SL, et al. Regulation of mouse bone marrow macrophage mannose receptor expression and activation by prostaglandin E and IFN-gamma. J Iimmunol. 1993;151(9):4973–4981. doi:10.4049/jimmunol.151.9.4973
   PubMed Web of Science ®Google Scholar
• Lane KB, Egan B, Vick S, et al. Characterization of a rat alveolar macrophage cell line that expresses a functional mannose receptor. J Leukoc Biol. 1998;64(3):345–350. doi:10.1002/jlb.64.3.345
   PubMed Web of Science ®Google Scholar
• Janus L, Piatkowski M, Radwan-Praglowska J. Microwave-assisted synthesis and characterization of Poly(L-lysine)-Based Polymer/carbon quantum dot nanomaterials for biomedical purposes. Materials. 2019;12(23):3825. doi:10.3390/ma12233825
   PubMed Web of Science ®Google Scholar
• Naha PC, Hsu JC, Kim J, et al. Dextran-coated cerium oxide nanoparticles: a computed tomography contrast agent for imaging the gastrointestinal tract and inflammatory bowel disease. Acs Nano. 2020;14(8):10187–10197. doi:10.1021/acsnano.0c03457
   PubMed Web of Science ®Google Scholar